CerRx, Inc. (CerRx) today [Thursday] announced that it has been awarded a non-diluting National Institute of Health (NIH) grant of $1.1M to support a Phase I study combining its two lead investigational compounds intravenous (IV) fenretinide and IV safingol. These drugs act together to specifically kill cancer cells by increasing certain toxic ‘ceramide’ waxes in cancer cells.

...

C. Patrick Reynolds, M.D., Ph.D., chief scientific officer of CerRx and director at the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine Cancer Center, said, “The combination of fenretinide plus safingol provides a very exciting and novel approach to selectively attacking cancer cells of many types in adults and children and we are delighted that this imporant clinical trial will be carried out here in Texas.”

Read the full story >>